All news

Starling Oncology plunges 33.9% as it guides 2026 revenue to $650M-$660M

Seeking Alpha · · AI-summarised by FinFlash

Starling Oncology shares sank 33.88% after the company forecast 2026 revenue of $650 million to $660 million and adjusted EBITDA of $4 million to $6 million. Management also said it is targeting 100% growth in capitated revenue in 2027. The sharp drop suggests investors were disappointed with the outlook, adding to a run of heavy single-stock reactions to guidance during a volatile earnings week on Wall Street.

So What?

The thin EBITDA guidance points to margin pressure; STLN may remain volatile until investors see evidence that the capitated revenue model delivers profitable growth.

Read original source

Understand the context

Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.